Biosimulation refers to the mathematical simulation of biological processes and systems. It is aided by computer and is used for model based calculation of biological systems and processes. TMR’s latest report forecasts strong growth for the global Biosimulation Market between 2011 and 2018. The market is expected to significantly gain from the increasing use of pharmacokinetic (PKPD) and pharmacodynamics, of which PKPD is the most widely used method in drug development.
Based on application, drug development and drug discovery are the two major segments in the global biosimulation market. Besides analyzing the factors responsible behind growth exhibited across the aforementioned segments, the report also presents a detailed assessment of the factors influencing the market’s growth across its major regional categories. Using Porter’s five forces analysis, it gauges the bargaining power of buyers and suppliers. The analysis also helps the report in presenting insights into the degree of competition prevailing in the market and the impending threat from new entrants and product substitutes. It thus compiles exhaustive information obtained by proven research methodologies, helping the readers get a better perspective of the market.
Request to View Brochure of Report -
TMR forecasts the global biosimulation market to grow at a considerable pace between 2016 and 2024. The increasing use of pharmacokinetic (PKPD) and pharmacodynamics modelling in pre-clinical development is expected to support the market’s growth significantly in the coming years. By application, the market is expected to witness rising demand from drug development and drug discovery segments.
The rising demand for advanced technologies to reduce the cost incurred on drug discovery and development is the chief factor aiding the market’s expansion. In addition, the increased healthcare spending, improved simulation, and the advent of modeling tools and advanced computer technologies bode well for the global biosimulation market. Despite witnessing positive opportunities, the absence of proper standardization in the biosimulation methodology has continued being a major cause of concern. Besides this, factors such as inadequate knowledge about biological processes and systems and the chances of drug failure in biosimulation pose threat to the market.
Nevertheless, with innovations on card, in the near future the market will be able to mitigate a majority of the aforementioned concerns and exhibit steady growth.
In terms of geography, North America is projected to exhibit highly lucrative opportunities for the enterprises operating in the global biosimulation market. Europe will hold the second-leading share. Regulatory bodies in both these regions are making efforts to promote advanced technologies in drug development and discovery. This also provides significant impetus to the overall market for biosumulation.
In Asia Pacific however the market will continue exhibiting slower growth as it is still at a nascent stage. Hence despite the benefits of biosimulation, the lack of skilled professionals and inadequate healthcare infrastructure will continue giving tough time to enterprises operating in the Asia Pacific biosimulation market.
Request to View ToC of the report –
Some of the most prominent players operating in the global biosimulation market are Certara, Schrodinger, ACD/Labs, Accelrys, Entelos, Simulation Plus, Physiomics, Rhenovia, Insilico Biotechnology, LeadScope, Insilico biosciences, Genedata, Archimedes, and Compugen. These companies are actively involved in encouraging collaborative strategies and product launches to expand their geographic footprint, finds Transparency Market Research (TMR) in a new study. Furthermore, many of them are also engaged in the launch of upgraded versions of their already popular products with improvements in functionalities enabling researchers and scientists to study the behavior patterns of different pharmaceutical dosage forms.